Dysphagia-optimised intensity-modulated radiotherapy vs standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS), published in Lancet Onco.
#ESTRONewsletter : bit.ly/3H2wqVp
#randomised #controlled #trial #radonc

Great editorial on SABR 💥 “Cancer recurrence is a morbid toxicity and lowering tumor dose to abide organ constraints may harm more than help patients”

✨ On 11 February, we’ll celebrate the #InternationalDayOfWomenAndGirlsInScience ! We're turning the spotlight on the outstanding women shaping the future of #Radonc at ESTRO. Meet Anna Kirby ESTRO President, reflecting on her path in the scientific world👉 bit.ly/49q8vLV

#WorldCancerDay #CloseTheCareGap 🧡

TACE vs. SBRT for HCC

TACE
🚫 📈 G3+ Toxicity.
🚫 Less cost-effective than RT, even if compared to carbon ions!
🚫 Invasive.
🚫Total ablation = the exception.
🚫LC ~40-50%.

SBRT
✅📉 G3+ Toxicity.
✅More cost-effective.
✅Non-invasive.
✅Total ablation = the rule.
✅ LC ~85%.

Spreading holiday cheer in the world of #radonc ! 🎄 Proud of our small dream team gathered around the Linac, transformed into a #Snowball . Kudos to each one for making a difference! Our commitment remains, driven by the care we provide for our patients! youngAIRO

A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation - International Journal of Radiation Oncology, Biology, Physics redjournal.org/article/S0360-…

I'm filled with pride for our outstanding #radonc team from UniversitàVanvitelli at #AIRO2023 Here's to our young trainees, committed to learning and striving for progress in the field of #radonc Your dedication is the driving force behind our future success!

PACE-B 5-years results presented at #ASTRO23 by Nicholas van As
👉 excellent outcome of >95% biochemical control in SBRT
👉 no difference in long-term toxicity

STANDARD OF CARE for favourable intermediate risk prostate cancer

Another excellent HN trial at #ASTRO23 , phase 3 HYPNO evaluating hypofractionated RT in LA HNSCC vs accelerated CRT. 55Gy/20 vs 66Gy/33. Results demonstrate non-inferior LRC and grade 3+ toxicity. Great data to have for patients requiring shorter courses of RT. Shlomo Koyfman

Today is #WorldCancerDay Radiotherapy play a crucial role in the overall management of cancer #Radiotherapysavelifes #supportradiation #AIRO Marie Curie Legacy Campaign

Article alert Vol 178

Sexual dysfunction in female patients with anal cancer treated with curative intent: A systematic review of the literature
Javier Mejia-Gomez et al.
doi.org/10.1016/j.rado…

thegreenjournal.com/article/S0167-…

Finally out. A humongous effort over nearly 2 decades led by Sarbani (who needs to change her 🆔 😬)

Never before and unlikely ever again 900 pts with oral cancer randomised! Only possible at TMC Radiation Oncology Tata Memorial Hospital ACTREC-TMC

Happy new year to all of us!

Article alert Vol 178

The role of radiologic extranodal extension in predicting prognosis and chemotherapy benefit for T1-2 N1 nasopharyngeal carcinoma: A multicenter retrospective study
Yu-Jun Hu et al.
doi.org/10.1016/j.rado…

thegreenjournal.com/article/S0167-…

New article alert (Vol. 178)

Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent CRT alone in Lymph-Node-Stage III NPC based on propensity score-matching
Zhi-Cheng Liu et al.

doi.org/10.1016/j.rado…

thegreenjournal.com/article/S0167-…

Despite my 'justified' absence at #AIRO2022 I am very proud of all my Colleagues attending the conference! Thank to you all, as you will update me on everything! #Residents #youngdoctors roberta grassi Emma D'Ippolito youngAIRO

Safety of SBRT for max 5 oligometastases: SABR-5 study
- n=281 pts, in 31% with > 1 oligometastasis
- grade 3+ SBRT toxicity <5%
- grade 2+ SBRT toxicity 18.6%
👉 I do not know any (local) treatment in metastatic pts with such a favorable safety profile !
ja.ma/3rgIV8b

A really interesting ' non-inferiority' meta-analysis for LA #HNSCC . In this Forrest Plot for OS ( read it from left to right ‼️) we see as the upper limit of CIs always cross the non-inferiority line ⛔(also in case of induction chemo💥). #radonc ⚡⚡⚡
doi.org/10.1007/s00405…

New in #PracticalRO : Updated early-stage anal cancer contouring guidelines from ECOG-ACRIN Cancer Research Group ➡️ bit.ly/3tYmPcg #RadOnc